Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.62 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.62 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | BRD4 | O60885 | 1/20 | 0.47 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.47 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.47 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 4/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.46 |
| ▸ | GABBR2 | O75899 | 3/20 | 0.46 |
| ▸ | GABBR1 | Q9UBS5 | 3/20 | 0.46 |
| ▸ | BLM | P54132 | 2/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.46 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29903923 | 1.00 | LMNA (0.62) | LMNAMAPK1CYP2C9CYP2C19MEN1 | |
| SCHEMBL6367 | 1.00 | LMNA (0.62) | LMNAMAPK1CYP2C9CYP2C19MEN1 | |
| SCHEMBL6366 | 1.00 | LMNA (0.62) | LMNAMAPK1CYP2C9CYP2C19MEN1 | |
| SCHEMBL11652701 | 0.98 | LMNA (0.60) | LMNAMAPK1CYP2C9CYP2C19MEN1 | |
| SCHEMBL8997384 | 0.94 | LMNA (0.56) | LMNAMAPK1CYP2C9CYP2C19MEN1 | |
| Chlorobenzene SCHEMBL8754828 | 0.94 | LMNA (0.68) | LMNAMAPK1CYP2C9CYP2C19MEN1 | |
| SCHEMBL7566668 | 0.92 | LMNA (0.54) | LMNAMAPK1CYP2C9CYP2C19MEN1 | |
| Deaminohydroxyvaline SCHEMBL9069626 | 0.88 | LMNA (0.50) | LMNAMAPK1CYP2C9CYP2C19MEN1 | |
| Alanine SCHEMBL11206225 | 0.88 | LMNA (0.50) | LMNAMAPK1CYP2C9CYP2C19MEN1 | |
| D-Alanine SCHEMBL11211250 | 0.88 | LMNA (0.50) | LMNAMAPK1CYP2C9CYP2C19MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117945937-B | Method for preparing high-optical-purity sulbactam besylate | 重庆华森制药股份有限公司 | 2024-07-30 | — | — | CN | claimed |
| CN-117945937-A | Method for preparing high-optical-purity sulbactam besylate | 重庆华森制药股份有限公司 | 2024-04-30 | — | — | CN | claimed |
| CN-108884081-B | Process for separating enantiomers of piperazine derivatives | 阿森纽荣股份公司 | 2022-11-01 | — | — | CN | claimed |
| CN-110373762-B | Preparation method of antibacterial blended yarn for underwear | 海盐县硕创服装研究所 | 2022-04-12 | — | — | CN | claimed |
| EP-3419974-B1 | PROCESS FOR THE SEPARATION OF ENANTIOMERS OF PIPERAZINE DERIVATIVES | ASCENEURON SA (CH) | 2021-05-05 | — | — | EP | claimed |
| US-10344021-B2 | Process for the separation of enantiomers of piperazine derivatives | ASCENEURON S A (CH) | 2019-07-09 | — | — | US | claimed |
| EP-3419974-A1 | PROCESS FOR THE SEPARATION OF ENANTIOMERS OF PIPERAZINE DERIVATIVES | Asceneuron SA (CH) | 2019-01-02 | — | — | EP | claimed |
| WO-2017144635-A1 | PROCESS FOR THE SEPARATION OF ENANTIOMERS OF PIPERAZINE DERIVATIVES | ASCENEURON S. A. (CH) | 2017-08-31 | — | — | WO | claimed |
| US-20060259999-A1 | Modified nitrilases and their use in methods for the production of carboxylic acids | BASF AKTIENGESELLSCHAFT (DE) | 2006-11-16 | — | — | US | claimed |
| EP-1599584-A1 | MODIFIED NITRILASES AND THEIR USE IN METHODS FOR THE PRODUCTION OF CARBOXYLIC ACIDS | BASF AKTIENGESELLSCHAFT (DE) | 2005-11-30 | — | — | EP | claimed |
| WO-2004076655-A1 | MODIFIED NITRILASES AND THEIR USE IN METHODS FOR THE PRODUCTION OF CARBOXYLIC ACIDS | BASF AKTIENGESELLSCHAFT (DE) | 2004-09-10 | — | — | WO | claimed |
| US-12398130-B2 | Acid addition salts of piperazine derivatives | ASCENEURON SA (CH) | 2025-08-26 | — | — | US | disclosed |
| CN-117945937-B | Method for preparing high-optical-purity sulbactam besylate | 重庆华森制药股份有限公司 | 2024-07-30 | — | — | CN | disclosed |
| CN-117945937-B | Method for preparing high-optical-purity sulbactam besylate | 重庆华森制药股份有限公司 | 2024-07-30 | — | — | CN | disclosed |
| CN-117945937-A | Method for preparing high-optical-purity sulbactam besylate | 重庆华森制药股份有限公司 | 2024-04-30 | — | — | CN | disclosed |
| US-4297489-A | CEPHALOSPORINS | BRISTOL-MYERS COMPANY (US) | 1981-10-27 | — | — | US | disclosed |
| EP-0009722-A1 | Optically active complex, alanine.Ring-substituted mandelic acid, and the method for producing the same | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 1980-04-16 | — | — | EP | disclosed |
| US-4172196-A | CEPHALOSPORINS | BRISTOL-MYERS COMPANY (US) | 1979-10-23 | — | — | US | disclosed |
| US-4112228-A | BACTERICIDES | BRISTOL-MYERS COMPANY (US) | 1978-09-05 | — | — | US | disclosed |
| US-3985738-A | ANTIBACTERIAL AGENTS | BRISTOL-MYERS COMPANY (US) | 1976-10-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10344021-B2 | Process for the separation of enantiomers of piperazine derivatives | CYP3A5, CYP4Z1, HTR5A | LMNA 1321/4885MAPK1 1627/4885CYP2C9 290/4885 |
| US-12398130-B2 | Acid addition salts of piperazine derivatives | DNPEP, GAA, SLC30A5 | LMNA 3606/4885MAPK1 3288/4885CYP2C9 747/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.